NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Forecast, Price & News $2.89 -0.05 (-1.70%) (As of 11:50 AM ET) Add Compare Share Share Today's Range$2.86▼$3.0050-Day Range$1.55▼$3.3052-Week Range$1.09▼$4.70Volume24,470 shsAverage Volume341,366 shsMarket Capitalization$113.89 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Brainstorm Cell Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside257.1% Upside$10.00 Price TargetShort InterestHealthy9.52% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.91Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.61) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector320th out of 1,006 stocksBiological Products, Except Diagnostic Industry42nd out of 167 stocks 3.5 Analyst's Opinion Consensus RatingBrainstorm Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Brainstorm Cell Therapeutics has a forecasted upside of 257.1% from its current price of $2.80.Amount of Analyst CoverageBrainstorm Cell Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.52% of the float of Brainstorm Cell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently decreased by 9.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBrainstorm Cell Therapeutics has received a 76.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for the nervous system", "Preclinical research services for physical health", and "Preclinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Brainstorm Cell Therapeutics is -0.66. Previous Next 2.7 News and Social Media Coverage News SentimentBrainstorm Cell Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Brainstorm Cell Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BCLI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.30% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.61% of the stock of Brainstorm Cell Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Brainstorm Cell Therapeutics (NASDAQ:BCLI) StockBrainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.Read More Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCLI Stock News HeadlinesMay 26, 2023 | americanbankingnews.comFY2023 EPS Estimates for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Boosted by Zacks Small CapMay 24, 2023 | msn.comBrainstorm Cell COO Setboun to leave company - filingMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 23, 2023 | finance.yahoo.comBCLI: Awaiting Adcom Date for NurOwn®…May 23, 2023 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Lifted to "Hold" at StockNews.comMay 19, 2023 | finance.yahoo.comBrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development SummitMay 18, 2023 | finance.yahoo.comWhile institutions own 23% of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), retail investors are its largest shareholders with 59% ownershipMay 17, 2023 | finance.yahoo.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2023 Earnings Call TranscriptMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 16, 2023 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Downgraded to "Sell" at StockNews.comMay 15, 2023 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 15, 2023 | finance.yahoo.comBrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 14, 2023 | americanbankingnews.comBrainstorm Cell Therapeutics (BCLI) to Release Quarterly Earnings on MondayMay 12, 2023 | msn.comBrainStorm Cell Therapeutics Q1 2023 Earnings PreviewMay 9, 2023 | finance.yahoo.comBrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate UpdateApril 30, 2023 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded at StockNews.comApril 17, 2023 | americanbankingnews.comShort Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Increases By 29.7%April 16, 2023 | americanbankingnews.comContrasting Brainstorm Cell Therapeutics (NASDAQ:BCLI) & Codiak BioSciences (NASDAQ:CDAK)April 8, 2023 | americanbankingnews.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to Post FY2023 Earnings of ($0.63) Per Share, Zacks Small Cap ForecastsApril 7, 2023 | finance.yahoo.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Is Expected To Breakeven In The Near FutureApril 6, 2023 | americanbankingnews.comStock Traders Purchase Large Volume of Call Options on Brainstorm Cell Therapeutics (NASDAQ:BCLI)April 5, 2023 | finance.yahoo.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call TranscriptApril 5, 2023 | americanbankingnews.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to Post Q1 2023 Earnings of ($0.16) Per Share, Zacks Small Cap ForecastsApril 4, 2023 | finance.yahoo.comBCLI: Preparing for Adcom for NurOwn®…April 3, 2023 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Price Target Raised to $10.00April 2, 2023 | benzinga.comShould You Buy Brainstorm Cell Therapeutics Inc (BCLI) in Biotechnology Industry?April 1, 2023 | seekingalpha.comBrainstorm Cell Therapeutics Inc. (BCLI) Q4 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCLI Company Calendar Last Earnings3/30/2023Today5/31/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCLI CUSIPN/A CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees43Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+240.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-6,929.48% Return on Assets-197.59% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-36.75Miscellaneous Outstanding Shares39,410,000Free Float35,350,000Market Cap$115.87 million OptionableOptionable Beta-0.38 Key ExecutivesChaim LebovitsPresident & Co-Chief Executive OfficerStacy R. LindborgCo-Chief Executive OfficerDavid SetbounChief Operating Officer & Executive Vice PresidentAlla PatlisChief Financial Officer & ControllerYael GothelfVice President-Scientific & Regulatory AffairsKey CompetitorsCidara TherapeuticsNASDAQ:CDTXAdverum BiotechnologiesNASDAQ:ADVMSolid BiosciencesNASDAQ:SLDBGenenta ScienceNASDAQ:GNTATalaris TherapeuticsNASDAQ:TALSView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 191,000 shares on 5/16/2023Ownership: 0.000%AIGH Capital Management LLCBought 1,459,095 shares on 5/15/2023Ownership: 3.978%XTX Topco LtdBought 12,227 shares on 5/15/2023Ownership: 0.033%Group One Trading L.P.Bought 40,400 shares on 5/12/2023Ownership: 0.000%Nelson Van Denburg & Campbell Wealth Management Group LLCBought 12,686 shares on 5/10/2023Ownership: 0.035%View All Institutional Transactions BCLI Stock - Frequently Asked Questions Should I buy or sell Brainstorm Cell Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCLI shares. View BCLI analyst ratings or view top-rated stocks. What is Brainstorm Cell Therapeutics' stock price forecast for 2023? 1 equities research analysts have issued 12 month price objectives for Brainstorm Cell Therapeutics' stock. Their BCLI share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 240.1% from the stock's current price. View analysts price targets for BCLI or view top-rated stocks among Wall Street analysts. How have BCLI shares performed in 2023? Brainstorm Cell Therapeutics' stock was trading at $1.64 at the start of the year. Since then, BCLI shares have increased by 79.3% and is now trading at $2.94. View the best growth stocks for 2023 here. Are investors shorting Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 2,870,000 shares, a drop of 9.2% from the April 30th total of 3,160,000 shares. Based on an average trading volume of 359,000 shares, the short-interest ratio is currently 8.0 days. Approximately 9.5% of the company's shares are sold short. View Brainstorm Cell Therapeutics' Short Interest. When is Brainstorm Cell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our BCLI earnings forecast. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings data on Thursday, March, 30th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP). What is Brainstorm Cell Therapeutics' stock symbol? Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI." Who are Brainstorm Cell Therapeutics' major shareholders? Brainstorm Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (3.98%), Susquehanna International Group LLP (0.00%), Raymond James & Associates (0.45%), Liberty Wealth Management LLC (0.41%), Group One Trading L.P. (0.00%) and TRU Independence Asset Management 2 LLC (0.12%). Insiders that own company stock include David Setboun, International Holdings Ltd Acc and Sankesh Abbhi. View institutional ownership trends. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Brainstorm Cell Therapeutics' stock price today? One share of BCLI stock can currently be purchased for approximately $2.94. How much money does Brainstorm Cell Therapeutics make? Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a market capitalization of $115.87 million. The biotechnology company earns $-24,280,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. How can I contact Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.brainstorm-cell.com. The biotechnology company can be reached via phone at (201) 488-0460 or via email at pshah@brainstorm-cell.com. This page (NASDAQ:BCLI) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.